| Citation: |
QU Jinghan, LIU Xin, TIAN Xin, AN Pengjiao, XU Tingting, ZHANG Bo. Comprehensive Clinical Evaluation of Nusinersen Based on Multi-criteria Decision Analysis Method[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1083-1090. DOI: 10.12290/xhyxzz.2024-0082
|
To provide a theoretical basis for different drug decision-making scenarios by conducting a comprehensive clinical evaluation of nusinersen.
Based on the method of multi-criteria decision analysis, a comprehensive clinical evaluation index system of nusinersen was established. This system, including core criterion model and contextualized criterion model, covered multiple evaluation dimensions such as safety, effectiveness, economy, and social attributes. The evidence of nusinersen in various criteria was summarized and integrated through systematic reviews. Then, different stakeholders were assigned weights and scores in various criteria of the core criterion model. Finally, a holistic value of nusinersen was estimatedthrough standardizing and combining the results in contextualized criterion model.
The criteria, type of therapeutic benefit disease severity (0.08±0.02), unmet needs (0.08±0.01), quality of evidence (0.08±0.01), effectiveness (0.08±0.01) and safety (0.08±0.02) received the greatest weights after standardization. The higher mean scores for nusinersen versus placebo for the treatment of spinal muscular atrophy were disease severity (4.8±0.4), innovation of the drug (4.7±0.6), expert consensus or clinical practice guidelines (4.5±0.6), effectiveness (4.0±1.0) and quality of evidence (4.0±0.8).The holistic value of nusinersen was 0.41. The overall impact of the contextualized model on the evaluation of the drug was 0.26, indicating that it may overestimate the comprehensive value of nusinersen.
The method of multi-criteria decision analysis proves the positive role that nusinersen plays in spinal muscular atrophy treatment.
| [1] |
Lasalvia P, Prieto-Pinto L, Moreno M, et al. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review[J]. Expert Rev Pharmacoecon Outcomes Res, 2019, 19(4): 409-420. DOI: 10.1080/14737167.2019.1633918
|
| [2] |
Baran-Kooiker A, Czech M, Kooiker C. Multi-criteria decision analysis (MCDA) models in health technology assessment of orphan drugs-a systematic literature review. Next steps in methodology development?[J]. Front Public Health, 2018, 6: 287. DOI: 10.3389/fpubh.2018.00287
|
| [3] |
Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Multi-criteria decision analysis for assessment and appraisal of orphan drugs[J]. Front Public Health, 2016, 4: 214.
|
| [4] |
Friedmann C, Levy P, Hensel P, et al. Using multi-criteria decision analysis to appraise orphan drugs: a systematic review[J]. Expert Rev Pharmacoecon Outcomes Res, 2018, 18(2): 135-146. DOI: 10.1080/14737167.2018.1414603
|
| [5] |
Blonda A, Denier Y, Huys I, et al. How to value orphan drugs? A review of European value assessment frameworks[J]. Front Pharmacol, 2021, 12: 631527. DOI: 10.3389/fphar.2021.631527
|
| [6] |
Zelei T, Molnár M J, Szegedi M, et al. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries[J]. Orphanet J Rare Dis, 2016, 11(1): 72. DOI: 10.1186/s13023-016-0455-6
|
| [7] |
尚俊美, 刘鑫, 陈丽萌, 等. 多准则决策分析在孤儿药综合评价中的应用进展[J]. 中国药学杂志, 2021, 56(22): 1785-1790.
Shang J M, Liu X, Chen L M, et al. Application progress of multi-criteria decision analysis in assessment of orphan drugs[J]. Chin Pharm J, 2021, 56(22): 1785-1790.
|
| [8] |
中国研究型医院学会罕见病分会, 中国罕见病联盟, 北京罕见病诊疗与保障学会, 等. 青少年成人脊髓性肌萎缩症临床诊疗指南[J]. 罕见病研究, 2023, 2(3): 377-397.
Rare Disease Society of Chinese Research Hospital Association, China Alliance for Rare Diseases, Beijing Society of Rare Disease Clinical Care and Accessibility, et al. Clinical practice guideline for adolescent & adult patients with spinal muscular atrophy[J]. J Rare Dis, 2023, 2(3): 377-397.
|
| [9] |
许婷婷, 刘鑫, 张翠莲, 等. 诺西那生治疗脊髓性肌萎缩症有效性及安全性研究进展[J]. 中国药学杂志, 2022, 57(17): 1413-1418.
Xu T T, Liu X, Zhang C L, et al. Research progress on the effectiveness and safety of Nusinersen in the treatment of spinal muscular atrophy[J]. Chin Pharm J, 2022, 57(17): 1413-1418.
|
| [10] |
北京协和医院罕见病多学科协作组, 中国罕见病联盟. 多准则决策分析应用于罕见病药品临床综合评价的专家共识(2022)[J]. 协和医学杂志, 2022, 13(2): 235-254. DOI: 10.12290/xhyxzz.2022-0013
Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital, National Rare Diseases Com-mittee. Expert consensus on the application of multi-criteria decision analysis in clinical comprehensive evaluation of orphan drugs (2022)[J]. Med J PUMCH, 2022, 13(2): 235-254. DOI: 10.12290/xhyxzz.2022-0013
|
| [11] |
Mercuri E, Finkel R S, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutri-tional care[J]. Neuromuscul Disord, 2018, 28(2): 103-115. DOI: 10.1016/j.nmd.2017.11.005
|
| [12] |
Finkel R S, Mercuri E, Meyer O H, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immuniza-tions; other organ systems; and ethics[J]. Neuromuscul Disord, 2018, 28(3): 197-207. DOI: 10.1016/j.nmd.2017.11.004
|
| [13] |
Ioos C, Leclair-Richard D, Mrad S, et al. Respiratory capacity course in patients with infantile spinal muscular atrophy[J]. Chest, 2004, 126(3): 831-837. DOI: 10.1378/chest.126.3.831
|
| [14] |
脊髓性肌萎缩症临床实践指南工作组. 脊髓性肌萎缩症临床实践指南[J]. 中国循证儿科杂志, 2023, 18(1): 1-12.
Clinical Practice Guidelines Working Group for Spinal Muscular Atrophy. Clinical practice guidelines for spinal muscular atrophy[J]. Chin J Evid Based Pediatr, 2023, 18(1): 1-12.
|
| [15] |
Mercuri E, Bertini E, Iannaccone S T. Childhood spinal muscular atrophy: controversies and challenges[J]. Lancet Neurol, 2012, 11(5): 443-452. DOI: 10.1016/S1474-4422(12)70061-3
|
| [16] |
Yao M, Ma Y, Qian R Y, et al. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study[J]. Orphanet J Rare Dis, 2021, 16(1): 7. DOI: 10.1186/s13023-020-01638-8
|
| [17] |
Wan H W Y, Carey K A, D'Silva A, et al. Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review[J]. Orphanet J Rare Dis, 2020, 15(1): 70. DOI: 10.1186/s13023-020-1339-3
|
| [18] |
Landfeldt E, Edström J, Sejersen T, et al. Quality of life of patients with spinal muscular atrophy: a systematic review[J]. Eur J Paediatr Neurol, 2019, 23(3): 347-356. DOI: 10.1016/j.ejpn.2019.03.004
|
| [19] |
Messina S, Frongia A L, Antonaci L, et al. A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy[J]. Neuromuscul Disord, 2019, 29(12): 940-950. DOI: 10.1016/j.nmd.2019.10.001
|
| [20] |
Guarga L, Badia X, Obach M, et al. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut)[J]. Orphanet J Rare Dis, 2019, 14(1): 157. DOI: 10.1186/s13023-019-1121-6
|
| [21] |
Garau M, Hampson G, Devlin N, et al. Applying a multicriteria decision analysis(MCDA)approach to elicit stakeholders' preferences in Italy: the case of obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL)[J]. Pharmacoecon Open, 2018, 2(2): 153-163. DOI: 10.1007/s41669-017-0048-x
|
| [22] |
Sussex J, Rollet P, Garau M, et al. A pilot study of multicriteria decision analysis for valuing orphan medicines[J]. Value Health, 2013, 16(8): 1163-1169. DOI: 10.1016/j.jval.2013.10.002
|
| [23] |
De Andrés-Nogales F, Cruz E, Calleja M Á, et al. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)[J]. Orphanet J Rare Dis, 2021, 16(1): 186. DOI: 10.1186/s13023-021-01809-1
|
| [24] |
Kolasa K, Zwolinski K M, Kalo Z, et al. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs[J]. Orphanet J Rare Dis, 2016, 11: 23. DOI: 10.1186/s13023-016-0388-0
|
| [25] |
Vermersch P, Martinelli V, Pfleger C, et al. Benefit-risk assessment of cladribine using multi-criteria decision analysis (MCDA) for patients with relapsing-remitting multiple sclerosis[J]. Clin Ther, 2019, 41(2): 249-260. e18. DOI: 10.1016/j.clinthera.2018.12.015
|
| [26] |
Jiménez A, Ais A, Beaudet A, et al. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)[J]. Orphanet J Rare Dis, 2018, 13(1): 220. DOI: 10.1186/s13023-018-0966-4
|
| [27] |
Broekhoff T F, Sweegers C C G, Krijkamp E M, et al. Early cost-effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and nusinersen (Spinraza) treatment for spinal muscular atrophy I in the Netherlands with relapse scenarios[J]. Value Health, 2021, 24(6): 759-769. DOI: 10.1016/j.jval.2020.09.021
|
| [28] |
Paracha N, Hudson P, Mitchell S, et al. Systematic literature review to assess economic evaluations in spinal muscular atrophy (SMA)[J]. Pharmacoeconomics, 2022, 40(Suppl 1): 69-89.
|
| [1] | XU Kexin, LI Guozhuang, WU Zhihong, ZHANG Jianguo, DISCO(Deciphering Disorders Involving Scoliosis & Comorbidities) Study Group, WU Nan. Progress in Clinical Diagnosis and Management of Short Stature in Ehlers-Danlos Syndromes[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 163-170. DOI: 10.12290/xhyxzz.2024-0173 |
| [2] | YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216 |
| [3] | LIU Huan, HUANG Xiaoling, DAI Mengying, GUO Jiejie, GAO feng. Clinical Characteristics and Inflammatory Markers of Omicron BA.5.2 Variant Infection in Hospitalized Patients and Their Predictive Role in Disease Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1038-1045. DOI: 10.12290/xhyxzz.2023-0055 |
| [4] | ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227 |
| [5] | QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, DU Hongqiang. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 373-378. DOI: 10.12290/xhyxzz.2023-0023 |
| [6] | LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271 |
| [7] | ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180 |
| [8] | Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital, National Rare Diseases Committee. Expert Consensus on the Application of Multi-criteria Decision Analysis in Clinical Comprehensive Evaluation of Orphan Drugs(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 235-254. DOI: 10.12290/xhyxzz.2022-0013 |
| [9] | MAIMAITI Nu-rong-gu-li, Hua-bing ZHANG, Xiao-ping XING. Clinical and Genetic Analysis of a Uyghur Patient with Gitelman's Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(6): 427-431. DOI: 10.3969/j.issn.1674-9081.2015.06.006 |
| [10] | Jie LIU, Yue-ping ZENG, Chun-xia HE, Qin LONG, Hong-zhong JIN, Qiu-ning SUN. Corticosteroids plus Intravenous Immunoglobulin in the Treatment of 7 Cases with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 381-385. DOI: 10.3969/j.issn.1674-9081.2012.04.004 |
| 1. |
刘晓玲，尉耘翠，曹旺，赵琴，郭嘉亮，阳创，周晓梅，何冠兰，刘彦会，赵华伟，王钰，郭吉芬，马明健，黄春芝，王秀玲，刘倩，谢国权，余静洁，刘婷，杨赛，王晓玲. 疾病修正治疗药物用于儿童脊髓性肌萎缩症的临床综合评价. 临床药物治疗杂志. 2025(03): 38-47 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: